UNSPSC 51334504: Psilocybin

This classification denotes a serotonin agonist and alkaloid with the molecular formula C12H17N2O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2RV7212BP0, chemically known as 4-phosphoryloxy-omega-n,n-dimethyltryptamine but generally known as psilocybin, which bears US NIH Compound Identifier 10624. European Medicines Agency schedules Psilocybine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10158MIG.

The term PSILOCYBINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). SMILES: CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O.

UNSPSC 51334504 Psilocybin is a Commodity-tier code that shows no recent state and local procurement activity aligned with its nominal scope. The three most recent opportunities posted under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023), a Texas Health and Human Services Commission RFI for direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026), and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026)—are pharmaceutical procurement efforts unrelated to psilocybin. The naloxone solicitation targets opioid-response supplies; the Texas RFI explores pharmacy benefit management structure; and the MMCAP RFP covers commodity generic drugs and over-the-counter items for state and local distribution networks. None of these opportunities involve controlled substances or clinical psilocybin therapies.

State and local procurement activity under this code does not currently reflect actual market activity in psilocybin products or services. The tagging mismatch suggests either data-entry error in the source system or inactive code status for state and local government purposes. Business development professionals should verify whether psilocybin procurement is occurring under alternate codes or whether state and local demand for this commodity remains negligible in current fiscal cycles. The geographic footprint of recent opportunities—Florida, Texas, and Minnesota—reflects routine state pharmaceutical and health-supply purchasing rather than psilocybin-specific demand signals.